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Abstract
Background: Our knowledge of immune-mediated inflammatory disease (IMID) aetiology and pathogenesis has
improved greatly over recent years, however, very little is known of the factors that trigger disease relapses (flares),
converting diseases from inactive to active states. Focussing on rheumatoid arthritis (RA), the challenge that we will
address is why IMIDs remit and relapse. Extrapolating from pathogenetic factors involved in disease initiation, new
episodes of inflammation could be triggered by recurrent systemic immune dysregulation or locally by factors
within the joint, either of which could be endorsed by overarching epigenetic factors or changes in systemic or
localised metabolism.
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Methods: The BIO-FLARE study is a non-randomised longitudinal cohort study that aims to enrol 150 patients with
RA in remission on a stable dose of non-biologic disease-modifying anti-rheumatic drugs (DMARDs), who consent
to discontinue treatment. Participants stop their DMARDs at time 0 and are offered an optional ultrasound-guided
synovial biopsy. They are studied intensively, with blood sampling and clinical evaluation at weeks 0, 2, 5, 8, 12 and
24. It is anticipated that 50% of participants will have a disease flare, whilst 50% remain in drug-free remission for
the study duration (24 weeks). Flaring participants undergo an ultrasound-guided synovial biopsy before
reinstatement of previous treatment. Blood samples will be used to investigate immune cell subsets, their activation
status and their cytokine profile, autoantibody profiles and epigenetic profiles. Synovial biopsies will be examined to
profile cell lineages and subtypes present at flare. Blood, urine and synovium will be examined to determine
metabolic profiles. Taking into account all generated data, multivariate statistical techniques will be employed to
develop a model to predict impending flare in RA, highlighting therapeutic pathways and informative biomarkers.
Despite initial recruitment to time and target, the SARS-CoV-2 pandemic has impacted significantly, and a decision
was taken to close recruitment at 118 participants with complete data.
Discussion: This study aims to investigate the pathogenesis of flare in rheumatoid arthritis, which is a significant
knowledge gap in our understanding, addressing a major unmet patient need.
Trial registration: The study was retrospectively registered on 27/06/2019 in the ISRCTN registry 16371380.
Keywords: Rheumatoid arthritis, Flare, Remission, Pathogenesis, DMARD withdrawal, DMARD cessation
Background
Rheumatoid arthritis (RA) is a relapsing and remitting
autoimmune disease characterised by chronic, polyarti-
cular joint inflammation, disability and premature mor-
tality [1]. Recent epidemiological studies have provided
critical aetiological insights that clearly invoke environ-
mental factors, such as cigarette smoking, interacting
with an immunogenetic predisposition to trigger breach
of tolerance – which, several years later, transitions from
asymptomatic ‘pre-RA’ to clinical disease [2, 3]. Once
established, the course of RA is usually characterised by
episodes of disease remission interspersed with periods
of active inflammation, despite the use of synthetic and
biological therapies. The pathophysiology of RA remains
incompletely understood, but a picture in which disrup-
tions of immune, stromal and epigenetic pathways all
contribute to a breakdown in self-tolerance has emerged
[4]. However, it is important to note that almost all data
underpinning this model are derived from patients with
active established disease. In contrast, much less is
known about RA in remission and virtually nothing
about the processes operating during the transition from
remission to flare. This remains a substantially under-
investigated area that the BIO-FLARE study aims to ad-
dress. An understanding of this aspect of RA pathogen-
esis will prove useful in preventing and treating flares.
Beyond this, however, it could also provide insights into
the genesis of clinical RA, the critical initiating events
wherein the immune system and stroma interact to gen-
erate chronic synovial inflammation during the transi-
tion from pre-RA to RA (Fig. 1).
The underpinning mechanism(s) of flare have been
difficult to study because they occur unpredictably.
However, we have recently established a highly relevant
human model that generates a ‘synchronized’ population
of RA patients in clinical remission, approximately 50%
of whom relapse within 6months, the remainder main-
taining remission. The Biomarkers of Remission in
Rheumatoid Arthritis (BioRRA) Study sought to identify
predictors of drug-free remission in RA. 23/44 (52%) of
participants in that study had an RA flare following
DMARD cessation [5]. We will study an equivalent co-
hort of participants in the BIO-FLARE study, to allow us
to understand the pathogenesis of flare in RA. Our hy-
pothesis is that, consequent upon epigenetic influences,
systemic immune factors integrate with the articular
stromal compartment to provoke localised flare, sup-
ported and sustained by metabolic changes in the joint.
We will use multivariate statistical techniques to develop
models to elucidate the longitudinal relationship of po-
tentially pathogenic pathways and identify those that are
associated with impending relapse in RA, highlighting
tractable therapeutic pathways and informative
biomarkers.
Our hypotheses are based on our own published and
ongoing studies, in extensive cohorts of early and estab-
lished RA patients, which we will now apply to patients
in remission [6–12]. The key biological question we are
addressing is how the known pathways of RA pathogen-




Our objectives are to carefully study our patient popula-
tion to address the aforementioned knowledge gap. The
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primary objective of the study is to measure the immune
dysregulation immediately prior to RA flare. In order to
interrogate the biology of flare we will focus on:
 Circulating immune cell subsets, their activation
status and cytokine profiles
 Autoantibody profiles and other circulating
mediators
 Synovial cellular subpopulations
 Metabolic profiles related to immune and/or
synovial activation
 Epigenetic profiles
The secondary objectives of the study are:
1. To corroborate baseline biomarkers predictive of
sustained DMARD-free remission, as identified by
the Biomarkers of Remission in Rheumatoid
Arthritis (BioRRA) study
2. To collect biological samples for future discovery
research
3. To establish the utility of physical activity
monitoring (via accelerometry) to assist in the early
detection of flare
Study design
The BIO-FLARE study is a multi-centre, open-label, pro-
spective, interventional, longitudinal cohort study under-
taken at three academic rheumatology centres within the
UK (Newcastle, Glasgow and Birmingham). The inter-
vention is complete cessation of non-biological DMAR
Ds (single or combination use of methotrexate, sulfasala-
zine and/or hydroxychloroquine). All participants who
fulfil eligibility criteria will stop their DMARD therapy
(without tapering). There is no randomisation involved.
Participants will be followed up for 6 months after
DMARD cessation or until the point of flare, whichever
is sooner.
Study population
The BIO-FLARE study aims to recruit 150 participants
who stop DMARDs and complete the study over a 24-
month period. After accounting for withdrawals and
subjects who fail to meet the remission criteria, we esti-
mate that we would need to recruit 181 participants to
achieve our target (see Fig. 2). Participants may be iden-
tified via routine rheumatology outpatient clinics, or
through existing databases.
Due to the SARS-CoV-2 pandemic, recruitment to the
study was halted from March to August 2020 according
to UK Department of Health guidance. After re-opening
recruitment, participation remained low, and with in-
creasing infection rates, there was low confidence that
the recruitment numbers would improve. After extensive
discussion that included trial statisticians, a decision was
taken to close recruitment at 118 participants with
complete data to enable timely analysis.
Eligibility criteria
Inclusion criteria
I. Diagnosis of RA according to the 1987 ACR or
2010 ACR/EULAR classification criteria (applied at
any time since diagnosis).
II. Current single or combination use of methotrexate,
sulfasalazine and/or hydroxychloroquine. No
Fig. 1 RA Aetiopathogenesis. Environmental factors act upon genetic predisposition to cause breach of tolerance (transition A); Unknown factors
act on an individual with pre-RA to trigger active RA (transition B); Treatment induces remission (transition C); Unknown factors trigger flare
(transition D). Colours denote what is well investigated (green), the focus of the study (orange) and additional processes that this study could
inform (pink)
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escalations in dose are permitted in the 6 months
prior to enrolment, although dose reductions in this
time are permitted.
III. Arthritis currently in remission, as judged clinically
by referring healthcare professional
IV. Patient and referring clinician willing to consider
DMARD withdrawal
V. Age 16 or over at time of symptom onset and 18 or
over at time of recruitment
Exclusion criteria
I. Inability to provide informed consent
II. Current participation or follow-up within another
ongoing clinical interventional trial
III. Current pregnancy, or pregnancy planned within
next 6 months
IV. Major surgery planned within the next 6 months (at
discretion of screening clinician)
V. Immunisation within the past 4 weeks
VI. Received oral, parenteral or intra-articular steroids
within past 3 months (topical, inhaled and intra-
nasal steroids are permitted)
VII.Use of any DMARD other than methotrexate,
sulfasalazine or hydroxychloroquine within the past
6 months (or past 12 months for leflunomide)
VIII.Increase in the dose of any DMARD in the 6
months prior to screening
IX. Use of biologic therapy within the past 6 months
X. Prior use of cell-depleting biologic therapies
XI. Haemoglobin < 9 g/L at baseline
XII.Contraindication to synovial biopsy – e.g. bleeding
diathesis or prolonged use of anticoagulant therapy




Participants attending a screening visit will have the op-
portunity to discuss the study further with an investiga-
tor before signing the consent form. At this point
participants are also given the opportunity to consent to
additional optional aspects of the study including a base-
line synovial biopsy, stool sample collection for micro-
biome analysis and wearing an accelerometer (GT9X
Actigraph) for the duration of the study to enable long-
term physical activity monitoring.
Demographic information is collected including RA
history, past medical history and medication history. A
general physical examination is performed and partici-
pants complete questionnaires capturing patient re-
ported outcome measures. Clinical and research blood
samples are taken and a urine sample is obtained. A
pregnancy test is carried out for women with child-
bearing potential. A full list of the schedule of events at
each visit is found in Table 1.
Following this visit, the disease activity score in 28
joints with C-reactive protein (DAS28-CRP) is calcu-
lated. The cut off for remission was set at DAS28-
CRP < 2.4. This is lower than some other remission
guidelines given the knowledge that DAS28 values
calculated using CRP are commonly lower than those
using ESR [15, 16]. If the DAS28-CRP score is < 2.4
and the participant has declined the optional baseline
synovial biopsy, then the participant is advised to im-
mediately discontinue their DMARD therapy. Partici-
pants who have a DAS28-CRP < 2.4 and have
provided additional consent for an optional baseline
synovial biopsy will be invited to attend for an add-
itional biopsy visit at their regional Hub site. They
Fig. 2 The BIO-FLARE Study overview with estimated patient numbers. Recruitment numbers are extrapolated from data observed in the BioRRA
study [5] and other published studies of DMARD withdrawal [13, 14]. Sample collection will occur at baseline, 2, 5, 8, 12 and 24 weeks after DMAR
D withdrawal, and also at the time of arthritis flare if this occurs
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will stop their DMARD treatment after the biopsy has
been performed. If the DAS28-CRP score is ≥2.4 then
the participant is withdrawn from the study at this
point, they are referred back to their rheumatology
team, and DMARD therapy is continued.
Follow-up period – day 14, 35, 56, 84, 168 and ad hoc
visits
At routine visits, adverse event recording and current
medications are noted. Clinical and research blood and
urine tests are taken and questionnaires are completed.


































Discuss Study / confirm willingness
to continue participation in study
X X X X X X X X X X X
Informed Consent for study X
Collect Demographics and medical
history
X
Record Current medication X X X X X X X X
General Physical examinationa X
Rheumatological Assessment -
DAS28-CRP
X X X X X X X X
Instruction to discontinue DMARDs
(if not opting for synovial Biopsy)
X
Instruction to discontinue DMARDs
(if opting for synovial biopsy)
X
Patient Reported Outcome Measures / Questionnaires
HAQ-DI X X X X
RAPID-3 X X X X X X X X
EuroQol 5D-5L X X X X X X X X
MFI X X X X
RA-FQ X X X X X X X X
FLARE-RA X X X X X X X X
Blood tests
Full Blood Count (FBC) X X X X X X X X
Inflammatory markers (ESR &
CRP)
X X X X X X X X
Antibodies (RhF & ACPA) X
Other clinical bloods (UE, LFT &
Clotting)
X X
Research blood tests (Serum,
EDTA, Tempus and Heparinised
samples)
X X X X X X X X
Other research tests
Urine Sample X X X X X X X X
Pregnancy testb X
Stool Sample (OPTIONAL) X X X X X X X X
Ultrasound assessment for
Synovial Biopsy (OPTIONAL AT








X X X X X X
aDepending on the circumstances of the consultation, physical examination may be indicated at any study visit to establish whether DAS28-CRP reflects arthritis
activity or infection etc. General Physical Examination is only mandatory at Screening
bMandatory at Screening but should be performed at any visit subsequently if routine questioning suggests a participant may be pregnant. Serum or urine tests
to be performed subsequently in line with local policy
cThis may be provided after the study visit once eligibility confirmed, either by post, or at the optional Baseline Synovial Biopsy Visit (if applicable)
Rayner et al. BMC Rheumatology            (2021) 5:22 Page 5 of 10
A joint examination is performed to allow calculation of
a DAS28-CRP.
If a participant feels that their arthritis is becoming
more active during the follow-up period, then they can
arrange an ad hoc visit. These visits follow the same for-
mat as the routine visits.
At any point in the study period if the participant is
found to have a DAS28-CRP ≥ 3.2 they are defined as
having a confirmed flare. If a participant is found to have
a DAS28-CRP ≥ 2.4 but < 3.2 they will return for a fur-
ther ad hoc assessment within 14 days. At the second as-
sessment if the DAS28-CRP ≥ 2.4 they will be defined as
a confirmed flare (Fig. 3).
Confirmed flare
If a participant has a confirmed flare (DAS28-CRP ≥ 3.2,
or DAS28-CRP ≥ 2.4 on 2 occasions within 14 days) an
ultrasound-guided synovial biopsy will be arranged to
take place within 7 days of flare confirmation. Following
the synovial biopsy, the participant will receive gluco-
corticoid therapy if needed, and will be discharged from
the study back to their referring team to rapidly recom-
mence DMARDs. A further review (telephone call or
face to face visit) will occur 4 weeks after a confirmed
flare to ensure the participants’ RA is back under con-
trol, that they have had contact with their referring
rheumatology team, and that they have resumed DMAR
D therapy. No study data will be collected at that visit.
Participant autonomy and safety
The participant has full autonomy throughout this study.
The participant information sheet makes it clear that
they may withdraw their consent at any time; for ex-
ample, they may opt not to stop or restart DMARD
therapy when it is otherwise indicated to do so in the
study protocol. The wishes of the participant will be
respected, although the participant will then be dis-
charged from the study and referred back to the clinical
(referring) team.
The trial clinician may withdraw a participant from
the study at any time if this is considered necessary, and
for any reason including:
I. Symptomatic deterioration
II. Participant withdrawal of consent
III. Significant protocol deviation or non-compliance,
including failure to attend for more than 2 consecu-
tive visits.
IV. An adverse event, such that discontinuation of
DMARDs is no longer appropriate, or renders the
participant unable to continue in the trial
V. Termination of the clinical study by the Sponsor
Fig. 3 Participant journey through the study. If the DAS28-CRP≥ 2.4 at the screening visit, the participant is referred back to their own
rheumatology team, remaining on DMARDs. All remaining participants stop their DMARDs at day 0 and are followed up with routine visits, or
patient requested ad-hoc visits for 24 weeks or until the point of flare
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VI. Investigator’s discretion that it is in the best interest
of the participant to withdraw
Participants who withdraw from the study will not be
replaced automatically as the target sample size has been
calculated to allow for withdrawals.
Clinical discretion
In certain circumstances, it may become clinically appar-
ent that a participant has a DAS28-CRP ≥ 2.4 owing to
an alternative clinical diagnosis other than their rheuma-
toid arthritis. Examples of this may include, but are not
limited to:
I. Concurrent infection causing a rise in blood
inflammatory markers or patient visual analogue
scale leading to a rise in DAS28-CRP above remis-
sion thresholds
II. Local trauma event causing joint pain/swelling or a
rise in patient visual analogue scale leading to a rise
in DAS28-CRP above remission thresholds
In such circumstances, and after agreement with the
participant, the research clinician has the discretion not
to refer back to the clinical team for restart of DMARD
therapy if this is felt to be clinically inappropriate. The
participant should continue in the study, but should
have an additional appointment review within 14 days. If
the participant still has a DAS28-CRP ≥ 2.4 at this add-
itional review, then they should normally be discharged
from the study and restart their DMARDs via their re-
ferring clinical team.
Similarly, in some circumstances it may become clinic-
ally indicated to restart DMARD therapy despite the
participant achieving a DAS28-CRP < 2.4 – for example,
to control extra-articular manifestations of RA not mea-
sured in the remission criteria, or flaring in non-DAS28
joints, e.g. the ankles, feet. In these circumstances, the
research clinician has the discretion to refer back to the
clinical team for restart of DMARD therapy if this is felt
to be clinically indicated at that time. The participant
would then also be discharged from the study.
Furthermore, the clinician has the discretion to ar-
range additional investigations on clinical grounds as re-
quired in response to adverse events.
Adverse events
Adverse events will be recorded at each study visit; the
investigator will determine the severity as mild, moder-
ate or severe, and ascertain any causal relationship with
the study intervention. Any serious adverse events will
be reported immediately to the chief investigator who
will inform the Sponsor and the Research Ethics
Committee (REC). A serious adverse event is any ad-
verse event which:
a. Results in death
b. Is life-threatening (i.e. an event in which the partici-
pant was at risk of death at the time of the event; it
does not refer to an event which hypothetically
might have caused death if it were more severe)
c. Requires hospitalisation, or prolongation of existing
hospitalisation
d. Results in persistent or significant disability or
incapacity
e. Is a congenital anomaly or birth defect
Following cessation of DMARD therapy, we expect
that approximately half of the participants will experi-
ence a confirmed flare of their arthritis requiring re-
sumption of DMARD therapy and potentially temporary
glucocorticoid treatment, without the need for hospital-
isation. We also expect that participants who consent to
synovial biopsy may experience temporary symptoms
(24–48 h) of mild joint pain, swelling or bruising at the
biopsy site, but that this is a safe and well tolerated pro-
cedure [17]. Joint pain, joint swelling and joint stiffness
will not be recorded as an adverse event throughout the
BIO-FLARE study.
Pregnancy
Pregnancy is associated with a diverse range of physio-
logical changes, and is often associated with a reduction
in rheumatoid arthritis activity. Pregnancy can therefore
be expected to greatly influence the underlying patho-
genic processes in RA and any associated biomarkers,
and thus pregnancy is an exclusion criterion for this
study.
Where pregnancy in a female participant becomes ap-
parent after the enrolment of the participant to the
study, this must be recorded as an adverse event. The
participant’s referring rheumatologist and GP must be
informed, and then the participant must be discharged
from the study, remaining off DMARD therapy. The
progress of the pregnancy should be followed to term,
with no additional follow-up required if the neonate is
healthy at birth.
Where the female partner of a male study participant
becomes pregnant during study participation, this should
also be recorded as an adverse event. The participant may
continue within the study. The progress of the pregnancy
should be followed to term, with no additional follow-up
required if the neonate is healthy at birth.
Trial governance
The trial management group (TMG) functions to pro-
vide operational oversight of the entire BIO-FLARE
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project including patient recruitment, clinical proce-
dures, laboratory procedures and finance. Any changes
to the study Protocol, Participant Information Sheet,
Consent Form or Standard Operating Procedures must
be reviewed and authorised by the TMG prior to
implementation.
As this is a non-CTIMP study, a Combined Trial
Oversight Committee (CTOC) will subsume the roles of
a Trial Steering Committee (TSC) and Data Monitoring
and Ethics Committee (DMC). The CTOC provides in-
dependent oversight of the BIO-FLARE project, particu-
larly with regard to patient recruitment and safety.
Independence is to be maintained by the use of open
and closed sessions for the CTOC and by limiting the
voting rights of the non-independent representatives.
Statistical considerations
The aims of the statistical analyses are to estimate and
understand the longitudinal stochastic relationship be-
tween the risk of flare and each of the markers in the
relevant biological pathways. The overall proportion
(confidence interval) of participants who flare by 24
weeks will be estimated using the actual time of flare
based on Kaplan-Meier estimates. Graphical representa-
tion and descriptive statistics of the longitudinal marker
measurements will indicate trends in markers over time,
to identify plausible differences in trends in participants
who flare and those who do not.
The association between markers and risk of flare will
be investigated in a series of descriptive univariate
models, based on analysis of each covariate in Cox pro-
portional hazards models, or parametric alternatives,
with time varying covariates to account for the longitu-
dinal nature of marker data, through attributing variabil-
ity at the participant level, time level and marker level.
Individual covariates may not be linear in their relation-
ship with outcome so the ‘best’ fitting non-linear rela-
tionship will be explored using Fractional Polynomial
transformation [18]. The magnitude of the relationship
of each marker with risk of flare will be described using
estimated beta coefficients (with confidence intervals)
accounting for variability at the time level and marker
level.
Data handling
Data, including the number of patients screened,
approached and interested in taking part, will be col-
lected via a log completed by staff conducting screening.
Trial data for individual participants will be collected by
each Principal Investigator (PI) or their delegated person
and recorded in the electronic case report form (eCRF)
for the trial. Participant identification within the eCRF
will be through a unique trial identifier number. A rec-
ord linking the participant’s name to the unique trial
identifier number will be held only in a locked room at
the trial site, and is the responsibility of the PI. As such,
participants cannot be identified from eCRFs. The Chief
Investigator (CI) or delegated person will monitor com-
pleteness and quality of data recording in eCRFs and will
correspond regularly with site PIs (or their delegated
team member) with the aim of capturing any missing
data where possible, and ensuring continuous high qual-
ity of data. No participant identifiable data will leave the
study site. The quality and retention of study data will
be the responsibility of the CI. All study data will be
retained in accordance with the latest directive on Good
Clinical Practice (GCP) and local policy.
All trial data will be stored securely in accordance with
GCP, and the Sponsor and Newcastle Clinical Trials
Unit (CTU) Standard Operating Procedures (SOPs). Any
personal identifiable information will be stored at the
study site for 10 years before secure disposal. Data will
be handled, computerised and stored in accordance with
the Data Protection Act 2018.
Discussion
The outlook for patients diagnosed with RA now is
vastly different compared with 30 years ago. With rapid
access to diagnosis and treatment, a large proportion of
patients with a new RA diagnosis can hope to achieve
remission or low disease activity [19]. The widespread
use of methotrexate and other disease modifying drugs
has changed the face of this chronic disease, which trad-
itionally resulted in chronic pain and disability. More re-
cently, the advent of biologic drugs has transformed the
treatment of those with moderate to severe disease,
allowing many patients to continue their normal lives
[20]. However, a large portion of patients who achieve
remission, subsequently flare. The unpredictable nature
of flares can cause disruption in home and working lives,
and there is a well-documented association between
rheumatoid arthritis and levels of anxiety and depression
[21]. This unpredictability also makes the scientific in-
vestigation of flares very difficult. There is a gap in our
knowledge of what triggers flares, and what pathophysio-
logical changes happen during the flare process. RA is
just one example of an immune-mediated relapsing re-
mitting disease. If more was understood about the
process of flare in RA, it could help to inform disease
flares in other IMIDs such as multiple sclerosis, inflam-
matory bowel disease and psoriasis.
Our previous study investigating the biomarkers of re-
mission in rheumatoid arthritis (BioRRA study) studied
a similar cohort of patients, half of whom flared over a
6-month period [5]. This finding is comparable with
other similar studies into remission and flare [13, 14,
22]. There is always an ethical consideration in a study
of this nature, given that patients who are previously
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well, with their disease in remission, are asked to stop
their medication. However, experience and our prior
work tell us that a significant number of patients are
keen to do this [23]. When consulting with our Newcas-
tle Patient and Public Involvement (PPI) group in the
planning stages, there was great appetite for such a
study. Patients might be experiencing side effects from
their medication, or the undesirable need for ongoing
blood tests. Some patients simply do not wish to take a
medication regularly, particularly if their disease has
been quiescent for years, as they may feel the medication
is not needed. As a speciality, rheumatologists are be-
coming more familiar with withdrawing medications
when patients are in remission, and indeed, DMARD
minimisation (though not necessarily complete cessa-
tion) in the setting of RA remission is now supported by
current RA management guidelines issued by the Ameri-
can College of Rheumatology (ACR) [24], and the Euro-
pean Alliance of Associations for Rheumatology
(EULAR) [25].
The design of the BIO-FLARE study allows a partici-
pant to be closely monitored in the period immediately
prior to clinical onset of flare. Clinical determinants are
collected and tracked over time, such as CRP, joint
counts and RAPID-3 scores, along with biological out-
comes. At each participant visit, blood is taken for re-
search, processed following SOPs and stored, with the
sample location information recorded in a laboratory in-
ventory management system (LIMS). The downstream
analysis of this blood will allow multiple questions to be
explored. Epigenetic profiling of PBMCs and CD14+
monocytes will be conducted allowing comparison to
those who stay in remission. Whole blood and PBMCs
will be analysed by flow cytometry to provide deep
immune-phenotyping of the samples. Serum and urine
samples will be used for metabolic profiling, and auto-
antibody profile and cytokine levels will also be investi-
gated using serum samples. Synovial tissue collected at
the point of flare will be analysed and, in certain cases,
can be paired with samples from the same participant
whilst in remission, prior to DMARD cessation.
The impact of the SARS-CoV-2 pandemic has had far
reaching consequences for all aspects of medical care,
including non-COVID research. After extensive discus-
sions amongst the Trial Management Group, including
statisticians, the decision was made to close recruitment
at 118 participants to enable timely data analysis. Strat-
egies to lessen the impact caused by the reduced sample
size on power will be considered including, for example,
restricting the number of biomarkers to be considered in
a multivariable risk model.
In summary, the novel nature of this study will allow
deep interrogation of the mechanisms occurring in the
days and weeks leading up to the point of RA flare. Our
aim is to further the understanding of the pathophysi-
ology of flare, develop strategies for intervention, and
also to prevent or predict flare. Furthermore, these same
mechanisms may also be at play during the onset of RA,
and thus may also serve to further our understanding of
the immunopathology of early stages of the disease.
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